Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

ter ended June 30, 2013. Non-GAAP net income for the quarter ended September 30, 2012 was $78.8 million, or $1.13 and $1.06 net income per basic and diluted share, respectively. Non-GAAP net income reported for the nine months ended September 30, 2013 was $43.3 million, or $0.60 and $0.57 net income per basic and diluted share, respectively, compared to non-GAAP net income of $54.4 million or $0.79 and $0.74 net income per basic and diluted share, respectively, for the nine months ended September 30, 2012. See "Use of Non-GAAP Financial Measures" below for a description of our non-GAAP measures. A reconciliation between certain generally accepted accounting principles ("GAAP") and non-GAAP measures is provided at the end of this press release.

GAAP net income for the quarter ended September 30, 2013 was $42.3 million, or $0.58 and $0.55 net income per basic and diluted share, respectively, compared to GAAP net income of $12.4 million, or $0.17 and $0.16 net income per basic and diluted share, respectively, for the quarter ended June 30, 2013. For the quarter ended September 30, 2012, GAAP net income was $75.6 million, or $1.09 and $1.02 net income per basic and diluted share, respectively. For the nine months ended September 30, 2013, GAAP net income was $2.8 million, or $0.04 net income per basic and diluted share, compared to GAAP net income of $45.9 million, or $0.66 and $0.62 net income per basic and diluted share, respectively, for the nine months ended September 30, 2012. Included in GAAP net income for the nine months ended September 30, 2013 and September 30, 2012 was stock-based compensation expense of $40.6 million and $8.5 million, respectively.

To date, the Company has earned milestone payments of $275 million under the Agreement. In addition to the $75 million, representing regulatory milestones earned under the Agreement during the three months ended September 30, 2013, the Company also earned four development milestone payments from Jans
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Enable Injections , developer of ... it easy and nearly painless for patients to self-inject ... has been named winner of the ,Buzz of BIO ... biotech sector.    Enable is one of only ... number of votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... Sept. 23, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... to its Scientific Advisory Board.  The new members are ... , PhD. Dr. Acker is a Senior ...
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
Breaking Medicine Technology:Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Avillion Appoints Jarrod Longcor as Chief Business Officer 2
(Date:9/23/2014)... 2014 Hope For The Warriors® is ... to be hosted in Boston, Massachusetts on Sunday, November ... This signature event honors the courage of our wounded ... fallen. Proceeds from the evening will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:9/23/2014)... Ithaca, New York (PRWEB) September 23, 2014 ... vulvodynia, interstitial cystitis, pudendal neuralgia, and other chronic pelvic or ... to lasting relief. , According to the Gallup poll, 1 ... suffer from chronic pelvic pain. Many of those women ... with their healthcare providers. The type of pain varies ...
(Date:9/23/2014)... 2014 People across Minnesota acknowledge that ... choices, but barriers are more prominent in the state’s ... Center for Prevention at Blue Cross and Blue Shield ... to healthy, affordable food and a lack of places ... About 60 percent of rural Minnesotans who responded to ...
(Date:9/23/2014)... 23, 2014). Researchers from the University of ... Krischek, investigated gene expression in normal vestibular nerves ... made: 1) there is negligible difference between VSs ... neurofibromatosis Type 2 (NF2), a genetic disorder; and ... tumors may be an excellent therapeutic target. Detailed ...
(Date:9/23/2014)... "Bee Towers” was featured on NewsWatch as part of its ... gadgets and services available to consumers. Mallory Sofastaii, a host ... and shared with viewers how it can hold tablets ... in the United States continue to climb. According to ... , For consumers who own a tablet but want ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:Mind Body Expert Launches Pelvic Pain Relief Program 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 3Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 4Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 5Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 3Health News:“Bee Towers”, a Floor Standing Tablet Holder by XAR Motion, was Featured on NewsWatch, a National Television Show, This Month 2
... EUR10.8 Million in ... ... (Nasdaq: CHDX ), an independent American provider of international,healthcare services ... that it has signed two contracts for the,supply of EUR10.8 million ...
... Because of the demographic changes, there will be a ... in 2004, the medical costs for the care of ... In their original article in the current edition of ... 105[26]: 467󈞵), the neurologist Tobias Neumann-Haefelin of the Johann ...
... in #1 respiratory hospital ranking, DENVER, July ... traditional boundaries of respiratory medicine into,exciting new areas ... Center will become National Jewish Health, effective immediately., ... put, this isn,t just about a name change. ...
... series of online NHS Health Guides,for people with long-term ... NHS Choices http://www.nhs.uk , These online guides ... diagnosis, and through to how to live and self ... be rolling out more,guides from the 60 most common ...
... BROOK, Ill. C JULY 11, 2008 -- A study ... of Radiology,s (ACR) CT colonography guidelines recommending that polyps ≤ ... applying them to an endoscopic database that collected information about ... also recommend that patients with one or two polyps 6 ...
... Placing 15 of its 16 Ranked Specialties Ahead of All ... Clinic Specialties Rated Among Nation,s Top Ten, ... Clinic,s cardiac care has been ranked No. 1 in the nation,according ... The survey recognizes Cleveland Clinic as one of the nation,s ...
Cached Medicine News:Health News:Chindex International, Inc. Announces CDC Contract Signing 2Health News:Chindex International, Inc. Announces CDC Contract Signing 3Health News:Chindex International, Inc. Announces CDC Contract Signing 4Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 2Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 3Health News:Online NHS Health Guides for Long-Term Conditions Released on NHS Choices 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 3Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 4Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 2Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 3
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
Inquire...
Microalbumin Linearity Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
Medicine Products: